Analyst consensus rating
Bicara Therapeutics Analyst Rating: Buy
BCAX is rated Buy by 14 analysts with a $33.50 target. As of 2026-08-24.
Direct answer
Bicara Therapeutics's consensus rating is Buy.
14 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $33.50.
Forecast evidence checked August 24, 2026.
Get free Bicara Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $23.68
- Average price target
- $33.50
- High price target
- $45.00
- Low price target
- $20.00
- Low target gap
- -15.5%
- Target upside
- +41.5%
- High target gap
- +90.1%
- Target range width
- 105.6%
- Consensus rating
- Buy
- Analysts
- 14
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Bicara Therapeutics?
Bicara Therapeutics has a verified Buy consensus. The same dataset has an average price target of $33.50.
How far are Bicara Therapeutics's low and high targets from the recorded price?
The low target implies -15.5%, while the high target implies +90.1%.
How many analysts are included in Bicara Therapeutics's consensus?
The verified consensus includes 14 analysts.
How is Bicara Therapeutics's target upside or downside calculated?
The average target of $33.50 is divided by the recorded price of $23.68, then one is subtracted to produce +41.5%. This does not guarantee a future return.
When was Bicara Therapeutics's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.